Compare SUNS & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SUNS | KLRS |
|---|---|---|
| Founded | 2023 | 2019 |
| Country | United States | United States |
| Employees | N/A | 20 |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.3M | 144.9M |
| IPO Year | N/A | N/A |
| Metric | SUNS | KLRS |
|---|---|---|
| Price | $7.87 | $6.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $8.75 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 116.1K | 80.5K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | ★ 15.31% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $70.81 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.84 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.46 | $2.14 |
| 52 Week High | $11.78 | $11.88 |
| Indicator | SUNS | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 41.11 | 45.92 |
| Support Level | $7.46 | $4.35 |
| Resistance Level | $10.27 | $7.18 |
| Average True Range (ATR) | 0.22 | 0.64 |
| MACD | 0.05 | 0.17 |
| Stochastic Oscillator | 58.73 | 64.02 |
Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS and debt-like preferred equity securities across CRE asset classes and investment mix to include high quality multi-family, condominiums, retail, office, hospitality, industrial, mixed use and specialty-use real estate.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.